(UroToday.com) At the 2021 ASCO Genitourinary Cancers Symposium (ASCO GU) practical applications of novel imaging and genomic approaches in the management of clinically localized prostate cancer session, Dr. Peter Carroll discussed active surveillance for prostate cancer as it stands in 2021. Dr. Carroll notes that active surveillance is a preferred form of treatment for many men, but should be seen, as well, as a response to the over-detection and over-treatment of prostate cancer brought about by widespread and repeated PSA screening. The uptake of active surveillance by the urology community helped pave the way for an upgraded assessment by The U.S. Preventive Services Task Force (USPSTF) on the early detection of prostate cancer.